Our key strengths

Management

Our Board members have a wealth of relevant experience and complementary skills that we believe is fundamental to the future success of the Group.

Robert Mansfield , Chief Executive Officer

With substantial international contacts and commercial and product development experience in the pharmaceutical sector including SmithKline Beecham and the bio-industry.

Dr Mike Snape , Chief Scientific Officer

Co-founder of Neuropharm Limited with 18 years’ experience in pharmaceutical R&D. Named as an inventor on 5 pharmaceutical patents including 3 new chemical entities.

Graham Yeatman, Chief Financial Officer

Ex-PricewaterhouseCoopers. A strong audit, tax, process re-engineering and corporate infrastructure background, plus small growth business, financial modelling and contract negotiation experience.

Non-executive Directors

Non-executive membership of the Board comprises Dr Graeme Hart, Dr Mike Hudson, Dr Gary Acton and Stephen Whybrow.

For more details on our management team and expertise, please see our Board of Directors page.

Market strategy

The Group development portfolio focuses on Autism and related neurodevelopmental disorders with few or no approved existing medicines.

The conditions targeted are typically chronic, severe, highly debilitating and under-served – as is the case with our two lead programs focused on Autism and Fragile X syndrome.

Market exclusivity

Due to the lack of licensed medicines for these selected conditions, in some cases we may be able to obtain Orphan Drug Designation (ODD) status for drugs developed by the Group.

ODD typically provides a period of market exclusivity with respect to the relevant product. We are on track for such a scenario with our lead program NPL-2008 in Autism and also NPL-2009 in Fragile X syndrome.

A reduced-risk product portfolio

By seeking new uses for known compounds we aim to reduce the risks and costs normally associated with drug development, and our pipeline products all benefit from a history of known safety profiles and pharmacological properties.

For example in our lead program NPL-2008, fluoxetine, which is no longer under patent protection, is one of the most widely prescribed CNS drugs in history – with an estimated 19 million patient years of exposure in the last 6 years.

Lowering development time through collaboration

Collaboration is also central to our strategy.

It is our vision to be the partner of choice for clinicians and patient advocacy organizations with an interest in Autism and other related conditions such as Fragile X syndrome. So far we have entered into two major collaborative agreements in the US.